Linear Health Sciences Bolsters Leadership Team

Linear Health Sciences has appointed Rob Headley as vice president of sales and business development, and Jessica Czamanski as director of product and regulatory affairs. The pair join the company as it looks to further commercialize the Orchid SRV tension-activated breakaway safety release valve, 
 
More than 342 million peripheral IVs are administered in the U.S. each year;¹ dislodgement and associated failure modes are estimated to cost the American healthcare system more than $2 billion annually.² The Orchid SRV, a sterile, single-use connector for needle-free access, makes return to treatment fast, simple, and clean, while improving both the patient and clinician experience. Placed between the existing IV extension set and general IV tubing connection, when tension (of up to 3.25 lbs.) acts on the IV line, the valve separates and seals off both sides of the IV, creating a sterile barrier. The clinician then restores the line simply by removing the separated halves and replacing them with a new, pre-packaged, sterile valve.
 
Headley, who will lead Linear’s sales pipeline and marketing efforts, has spent nearly 20 years in the life sciences industry, most recently at Baxter International as vice president of sales, marketing and U.S. commercial training. His responsibilities at Linear Health Science include relationship management with integrated delivery networks and distributors, and helping bring to life an innovation pipeline to support patients and clinicians alike.
 
Czamanski, an experienced quality and regulatory expert who has collaborated with Linear for more than four years, heads Linear’s product portfolio and international expansion efforts, using her knowledge and expertise to expand the Linear SRV’s footprint.
 
“We’re focused on advancing the standard of care in vascular access and other medical tubing applications, beginning with catheter dislodgement,” Linear Health Sciences Co-Founder/CEO Dan Clark said. “We expect the expertise Rob and Jessica bring to the table to be invaluable as we look to improve patient outcomes, while adding value to the healthcare system. Developing the right team to continue advancing the standard of care for patients and clinicians is foundational to that process.”
 
Linear Health Sciences won an Innovative Technology Award for Orchid SRV from Vizient, making the device available to hospital customers through a non-exclusive contract with the group purchasing organization (GPO). Additionally, the device is available nationwide and across Canada. Qualified clinical evaluations of Orchid SRV will continually quantify device utilization, driving Linear Health Science’s next generations of innovation.
 
“Linear’s technology platform is not just poised to change the standard of care for catheter dislodgement, but also to improve outcomes in our most vulnerable patient populations,” Headley said. “The vascular access market has had little or no innovation over the last decade. The Orchid SRV is a breakthrough solution that prevents some of the most critical catheter-related issues for patients.” 
 
Linear Health Sciences has developed a proprietary, breakaway safety valve technology designed to improve the use of medical tubing in hospitals. The platform technology was developed to increase the safety and satisfaction of patients, caregivers, and healthcare facilities, while dramatically reducing costs. The company’s initial products include the Orchid SRV for use in IV catheter therapy and the Orchid SRV Type D device for use in surgical/wound, nephrostomy and abscess drainage. 

References 
¹ ata research report
² lm, et al. “Accepted but unacceptable: peripheral IV catheter failure” J Infus Nurs May-Jun 2015;38(3):189-203. doi: 10.1097/NAN.0000000000000100